Atlas Trials

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Clinical trial NCT05176080 · TERMINATED

Trial details

NCT number
NCT05176080
Sponsor
Henan Cancer Hospital
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2021-12-08
Primary completion
2024-07-03
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.